<DOC>
	<DOCNO>NCT02211235</DOCNO>
	<brief_summary>Current guideline diagnosis management cystic fibrosis ( CF ) relate diabetes recommend treatment diabetes base diagnostic criterion derive adult type 2 diabetes . Increasing evidence support treat early glucose abnormality cystic fibrosis patient target CF specific outcome , include lung function nutrition ( BMI ) . However , criterion time start insulin therapy ` prediabetic ' state unclear . A accurate characterization blood sugar variability youth without CF help u good interpret continuous glucose monitor ( CGM ) find patient CF prediabetes diabetes accurately identify individual great risk disease progression .</brief_summary>
	<brief_title>Continuous Glucose Monitoring Controls With Without Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Healthy control ( n=35 ) 1 . Age 1025 year 2 . BMI &lt; 85th percentile 3 . Baseline health enrollment CF control ( n=35 ) 1 . Age 1025 year 2 . Diagnosis cystic fibrosis ( newborn screen , sweat chloride testing , genetic testing ) 3 . Baseline health enrollment ( inclusion/exclusion criterion CF patient base lung function , BMI , pancreatic insufficiency , genotype ) CF prediabetes &amp; CFRD ( n=60 ) 1 . Age 1025 year 2 . Diagnosis cystic fibrosis ( newborn screen , sweat chloride testing , genetic testing ) 3 . History abnormal oral glucose tolerance testing ( 2hglucose &gt; 140 , FPG &gt; 100,1hr glucose &gt; 200 ) 4 . If take medication affect glucose metabolism ( ex . Insulin , insulin sensitizer , glucocorticoid , atypical antipsychotic ) , stable dose past 3 month Healthy control 1 . Known diagnosis diabetes prediabetes ( include type 1 , type 2 , MODY ) , abnormal OGTT ( ie . FPG ≥100 2hr ≥140 mg/dl ) HbA1c ≥ 5.7 % 2 . BMI ≥85th percentile 3 . Chronic disease may affect glucose metabolism use medication affect glucose metabolism past 3 month ( ex . Insulin , insulin sensitizer , glucocorticoid , atypical antipsychotic ) 4 . Presence type 1 diabetes autoantibody individual first degree relative type 1 diabetes ( include first degree relative previous negative autoantibody screen perform part participation study TrialNet study Barbara Davis Center ) 5 . Acute illness ( ex . Asthma exacerbation , gastroenteritis , febrile illness ) 6 . Pregnancy CF participants 1 . Diagnosis type 1 diabetes , type 2 diabetes , MODY 2 . Varying dos medication affect glucose metabolism past 3 month 3 . Pulmonary exacerbation associate hospitalization , systemic steroid requirement precede 6 week 4 . Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>Healthy Controls</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Cystic Fibrosis Related Diabetes ( CFRD )</keyword>
	<keyword>CFRD</keyword>
</DOC>